Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonggi Choi

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
The American Journal of Gastroenterology|December 16, 2025
Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 DiabetesJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
The American Journal of Gastroenterology|January 9, 2023
Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated CirrhosisJiwon Yang, Won-Mook Choi, Ju Hyun Shim, et al.
JAMA Internal Medicine|March 17, 2025
Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver DiseaseJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
Journal of Hepatocellular Carcinoma|July 8, 2024
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular CarcinomaYe Rim Kim, Sung Won Chung, Min-Ju Kim, et al.
Gut|October 23, 2017
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis BGi-Ae Kim, Young-Suk Lim, Seungbong Han, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 28, 2021
Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer TreatmentSun Yoo, Danbi Lee, Ju Hyun Shim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2025
GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score MatchingJonggi Choi, Tushar Kamath, Vy H Nguyen, et al.
Hepatology Communications|April 13, 2026
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetesJonggi Choi, Gabby Mitchell, Vy H Nguyen, et al.
Clinical and Molecular Hepatology|November 11, 2025
Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate FibrosisJonggi Choi, Daniel Fulop, Vy H Nguyen, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulationJonggi Choi, Ana Verma, Vy H Nguyen, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
The American Journal of Gastroenterology|December 16, 2025
Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 DiabetesJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
The American Journal of Gastroenterology|January 9, 2023
Low Level of Hepatitis B Viremia Compared With Undetectable Viremia Increases the Risk of Hepatocellular Carcinoma in Patients With Untreated Compensated CirrhosisJiwon Yang, Won-Mook Choi, Ju Hyun Shim, et al.
JAMA Internal Medicine|March 17, 2025
Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver DiseaseJonggi Choi, Vy H Nguyen, Eric Przybyszewski, et al.
Journal of Hepatocellular Carcinoma|July 8, 2024
Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular CarcinomaYe Rim Kim, Sung Won Chung, Min-Ju Kim, et al.
Gut|October 23, 2017
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis BGi-Ae Kim, Young-Suk Lim, Seungbong Han, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 28, 2021
Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer TreatmentSun Yoo, Danbi Lee, Ju Hyun Shim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2025
GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score MatchingJonggi Choi, Tushar Kamath, Vy H Nguyen, et al.
Hepatology Communications|April 13, 2026
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetesJonggi Choi, Gabby Mitchell, Vy H Nguyen, et al.
Clinical and Molecular Hepatology|November 11, 2025
Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate FibrosisJonggi Choi, Daniel Fulop, Vy H Nguyen, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulationJonggi Choi, Ana Verma, Vy H Nguyen, et al.
Pageof 14